GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NASDAQ:CATB
Delisted

Catabasis Pharmaceuticals Stock Price (Quote)

$3.36
+0.195 (+6.16%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $3.02 $6.17 Friday, 27th May 2022 CATB stock ended at $3.36. This is 6.16% more than the trading day before Thursday, 26th May 2022. During the day the stock fluctuated 6.65% from a day low at $3.16 to a day high of $3.37.
90 days $3.02 $7.25
52 weeks $1.20 $10.26

Historical Catabasis Pharmaceuticals prices

Date Open High Low Close Volume
2019-03-27 $7.14 $7.35 $7.10 $7.29 100 986
2019-03-26 $7.30 $7.32 $7.00 $7.13 84 111
2019-03-25 $7.27 $7.42 $7.05 $7.25 206 865
2019-03-22 $7.39 $7.63 $7.17 $7.30 280 704
2019-03-21 $7.38 $7.85 $7.29 $7.46 550 636
2019-03-20 $7.24 $7.73 $7.17 $7.45 336 608
2019-03-19 $7.35 $7.40 $6.77 $7.11 318 705
2019-03-18 $7.05 $7.66 $6.70 $7.35 722 267
2019-03-15 $5.81 $6.72 $5.73 $6.71 606 518
2019-03-14 $5.95 $5.95 $5.62 $5.80 281 413
2019-03-13 $5.68 $5.95 $5.57 $5.60 206 156
2019-03-12 $5.70 $5.78 $5.46 $5.64 308 516
2019-03-11 $5.77 $5.87 $5.51 $5.61 327 160
2019-03-08 $5.20 $5.41 $5.00 $5.41 441 604
2019-03-07 $4.81 $5.05 $4.81 $5.02 238 689
2019-03-06 $4.82 $4.90 $4.70 $4.82 83 750
2019-03-05 $5.02 $5.02 $4.76 $4.86 76 510
2019-03-04 $5.00 $5.06 $4.81 $4.97 127 381
2019-03-01 $4.82 $4.92 $4.73 $4.90 65 396
2019-02-28 $4.70 $5.00 $4.62 $4.82 97 161
2019-02-27 $4.98 $5.03 $4.90 $4.93 61 838
2019-02-26 $5.07 $5.07 $4.86 $4.97 118 322
2019-02-25 $4.98 $5.10 $4.90 $4.96 183 896
2019-02-22 $4.86 $4.95 $4.70 $4.90 280 565
2019-02-21 $4.59 $4.80 $4.56 $4.80 219 991
Click to get the best stock tips daily for free!

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia i... CATB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT